^
Association details:
Biomarker:No biomarker
Cancer:Fallopian Tube Cancer
Drug:Lynparza (olaparib) (PARP inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:...for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy.
Evidence Level:
Sensitive: A1 - Approval
New
Excerpt:
Lynparza is indicated as monotherapy for the:..maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Acceptable Recurrence Therapies for…Fallopian tube cancer: Targeted Therapy...Olaparib